Program
Pemetrexed
Also written as “pemetrexed”, “ALIMTA” and “Pemetrexed/Cisplatin”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Neoplasms · Ovarian Neoplasms · Colorectal Neoplasms, led by 9 companies.
Drug pagePemetrexed: every studyMany companies study it; this page follows only the 108 they lead. All 434 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 940 open or running | phase 4since Sep 22, 2006 | Apr 29, 2002 | none ahead |
| Hoffmann-La Rocheits history only | 72 open or running | phase 3since Aug 18, 2009 | Aug 18, 2009 | Jun 30, 2027phase 3 · NCT05112965 |
| Betta Pharmaceuticalsits history only | 10 open or running | phase 4since Mar 31, 2014 | Mar 31, 2014 | none ahead |
| Hikma Pharmaceuticalsits history only | 10 open or running | phase 4since Feb 26, 2018 | Feb 26, 2018 | none ahead |
| Johnson & Johnsonits history only | 11 open or running | phase 3since Aug 31, 2020 | Aug 31, 2020 | none ahead |
| NovoCureits history only | 10 open or running | phase 2since Mar 19, 2015 | Mar 19, 2015 | none ahead |
| Polaris Groupits history only | 10 open or running | phase 3since Mar 5, 2016 | Mar 5, 2016 | none ahead |
| Shanghai Miracogenits history only | 11 open or running | phase 3since Feb 22, 2023 | Feb 22, 2023 | none ahead |
| Takedaits history only | 10 open or running | phase 2since Jun 22, 2006 | Jun 22, 2006 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Parexel, Daiichi Sankyo, Arcus Biosciences, Ono Pharmaceutical and Prologue Research International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since May 10, 2006.
- Jul 8, 20102 phase 2 studies in Carcinoma, Non-Small-Cell LungEli Lilly · NCT01160744, NCT01165021
- Aug 19, 2010Phase 2 study in Non-Squamous Non-Small Cell Lung CancerHoffmann-La Roche · NCT01185847 · 90 enrolled · Belgium, France, Germany and more
- Nov 2, 20112 phase 2 studies in Carcinoma, Non-Small-Cell LungEli Lilly · NCT01473563, NCT01469000
- Dec 19, 2011Phase 2 study in Non-Squamous Non-Small Cell Lung CancerHoffmann-La Roche · NCT01496742 · 259 enrolled · United States, Argentina, France and more
- Mar 31, 2014Betta Pharmaceuticals’ first study: phase 4 study in AdenocarcinomaNew to Betta PharmaceuticalsBetta Pharmaceuticals · NCT02103257 · 192 enrolled · China
- Mar 19, 2015NovoCure’s first study: phase 2 study in Mesothelioma, MalignantNew to NovoCureNovoCure · NCT02397928 · 82 enrolled · Belgium, France, Germany and more
- Mar 5, 2016Polaris Group’s first study: phase 3 study in MesotheliomaNew to Polaris GroupPolaris Group · NCT02709512 · 249 enrolled · United States, Australia, Italy and more
- Jun 5, 2017Phase 3 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT03178552 · 1,000 enrolled · United States, Argentina, Australia and more
- Nov 7, 2017Phase 2 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT03337698 · 314 enrolled · United States, Australia, France and more
- Feb 26, 2018Hikma Pharmaceuticals’ first study: phase 4 study in Carcinoma, Non-Small-Cell LungNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT03460678 · 9 enrolled · Jordan, Lebanon
- Aug 31, 2020Johnson & Johnson’s first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to Johnson & JohnsonJohnson & Johnson · NCT04538664 · 308 enrolled · United States, Australia, Belgium and more
- Nov 2, 2021Phase 3 study in NeoplasmsHoffmann-La Roche · NCT05112965 · 49 enrolled · China
- Feb 22, 2023Shanghai Miracogen’s first study: phase 3 study in Advanced or Metastatic Urothelium CancerNew to Shanghai MiracogenShanghai Miracogen · NCT05754853 · 290 planned · China
- Oct 1, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT06624059 · 11 enrolled · Australia, Brazil, Chile and more
Ahead
- Jun 30, 2027Primary completion: phase 3 study in NeoplasmsHoffmann-La Roche · NCT05112965
- Jun 30, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT03178552
TargetBeta
“Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor; Dihydrofolate reductase inhibitor”ChEMBL 37, by rule
Studies
The newest 60 of 108 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06624059Carcinoma, Non-Small-Cell Lung · Australia, Brazil, Chile and more | 3 | Completed | Hoffmann-La Roche | Jul 31, 2026 | 11 |
| NCT05754853Advanced or Metastatic Urothelium Cancer · China | 3 | Recruiting | Shanghai Miracogen | Oct 2025 | 290 |
| NCT05112965Neoplasms · China | 3 | Active, not recruiting | Hoffmann-La Roche | Jun 30, 2027 | 49 |
| NCT04538664Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 3 | Active, not recruiting | Johnson & Johnson | May 3, 2023 | 308 |
| NCT03460678Carcinoma, Non-Small-Cell Lung · Jordan, Lebanon | 4 | Terminated | Hikma Pharmaceuticals | Nov 14, 2018 | 9 |
| NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 2 | Terminated | Hoffmann-La Roche | Oct 14, 2025 | 314 |
| NCT03178552Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Hoffmann-La Roche | Jun 30, 2027 | 1,000 |
| NCT02709512Mesothelioma · United States, Australia, Italy and more | 3 | Completed | Polaris Group | Aug 15, 2022 | 249 |
| NCT02397928Mesothelioma, Malignant · Belgium, France, Germany and more | 2 | Completed | NovoCure | Apr 2018 | 82 |
| NCT02103257Adenocarcinoma · China | 4 | UNKNOWN | Betta Pharmaceuticals | Mar 2016 | 192 |
| NCT01496742Non-Squamous Non-Small Cell Lung Cancer · United States, Argentina, France and more | 2 | Completed | Hoffmann-La Roche | Nov 2015 | 259 |
| NCT01469000Carcinoma, Non-Small-Cell Lung · China, Japan, Korea, Republic of and more | 2 | Completed | Eli Lilly | Apr 2015 | 195 |
| NCT01473563Carcinoma, Non-Small-Cell Lung · Sweden, United Kingdom | 2 | Completed | Eli Lilly | Sep 2013 | 52 |
| NCT01185847Non-Squamous Non-Small Cell Lung Cancer · Belgium, France, Germany and more | 2 | Completed | Hoffmann-La Roche | Sep 2012 | 90 |
| NCT01165021Carcinoma, Non-Small-Cell Lung · Italy | 2 | Completed | Eli Lilly | Jul 2013 | 19 |
| NCT01160744Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 2 | Completed | Eli Lilly | Jan 2014 | 280 |
| NCT01087970Head and Neck Neoplasms · United States | 2 | Completed | Eli Lilly | Aug 2013 | 69 |
| NCT01057589Head and Neck Neoplasms · Belgium, France, Germany and more | 2 | Completed | Eli Lilly | Feb 2012 | 66 |
| NCT01020786Carcinoma, Non-Small-Cell Lung · Japan | 4 | Completed | Eli Lilly | Mar 2011 | 109 |
| NCT01017874Carcinoma, Non-Small-Cell Lung · Hong Kong, Korea, Republic of, Singapore and more | 3 | Completed | Eli Lilly | Apr 2013 | 236 |
| NCT01005680Carcinoma, Non-Small-Cell Lung · China | 3 | Completed | Eli Lilly | Nov 2012 | 256 |
| NCT01004250Carcinoma, Non-Small-Cell Lung · Denmark, Germany, Italy and more | 2 | Completed | Eli Lilly | Nov 2012 | 109 |
| NCT01000480Carcinoma, Non-Small-Cell Lung · France, Germany, Italy and more | 2 | Completed | Eli Lilly | Jan 2013 | 90 |
| NCT00961415Non-Squamous Non-Small Cell Lung Cancer · France, Germany, Greece and more | 3 | Completed | Hoffmann-La Roche | May 2011 | 376 |
| NCT00948675Carcinoma, Non-Small-Cell Lung · United States | 3 | Completed | Eli Lilly | Jan 31, 2013 | 361 |
| NCT00887549Carcinoma, Non-Small-Cell Lung · Ireland, United Kingdom | 2 | Completed | Eli Lilly | Jul 2010 | 70 |
| NCT00867009Carcinoma, Non-Small-Cell Lung · Austria, Germany, Greece and more | 2 | Completed | Eli Lilly | May 2011 | 113 |
| NCT00789373Carcinoma, Non-Small-Cell Lung · Australia, Belgium, Finland and more | 3 | Completed | Eli Lilly | Jun 2010 | 939 |
| NCT00762034Carcinoma, Non-Small-Cell Lung · United States | 3 | Completed | Eli Lilly | Apr 2012 | 939 |
| NCT00686959Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Oct 2014 | 598 |
| NCT00606021Carcinoma, Non-Small-Cell Lung · Egypt, Lebanon, Saudi Arabia | 2 | Completed | Eli Lilly | Dec 2010 | 106 |
| NCT00550173Carcinoma, Non-Small-Cell Lung · Brazil, China, Hong Kong and more | 2 | Completed | Eli Lilly | Jan 2012 | 247 |
| NCT00529100Carcinoma, Non-Small-Cell Lung · Canada | 2 | Completed | Eli Lilly | Aug 2010 | 49 |
| NCT00523419Osteosarcoma · France, Germany, Italy and more | 2 | Completed | Eli Lilly | Jun 2009 | 32 |
| NCT00520936Osteosarcoma · United States | 2 | Completed | Eli Lilly | Feb 2010 | 72 |
| NCT00520676Carcinoma, Non-Small-Cell Lung · Australia, Brazil, China and more | 3 | Completed | Eli Lilly | Jul 2010 | 260 |
| NCT00494026Small Cell Lung Carcinoma · Italy, Poland, Spain and more | 2 | Terminated | Eli Lilly | Oct 2008 | 4 |
| NCT00490373Pancreatic Neoplasms · Germany | 2 | Completed | Eli Lilly | 52 | |
| NCT00489983Carcinoma, Non-Small-Cell Lung · Germany, Italy, United Kingdom | 2 | Completed | Eli Lilly | 91 | |
| NCT00489359Ovarian Neoplasms · Argentina, Canada, Germany and more | 2 | Completed | Eli Lilly | Feb 2010 | 86 |
| NCT00475657Small Cell Lung Carcinoma · Spain | 2 | Terminated | Eli Lilly | Apr 2008 | 5 |
| NCT00461786Ovarian Neoplasms · United States | 2 | Completed | Eli Lilly | Oct 2007 | 51 |
| NCT00447421Small Cell Lung Carcinoma · Belgium, Netherlands | 2 | Terminated | Eli Lilly | May 2008 | 9 |
| NCT00447057Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy. · Austria, Germany, Hungary and more | 2 | Completed | Eli Lilly | Jul 2010 | 204 |
| NCT00415194Head and Neck Neoplasms · United States, Argentina, Belgium and more | 3 | Completed | Eli Lilly | Mar 2010 | 795 |
| NCT00415168Stomach Neoplasms · Russian Federation | 2 | Completed | Eli Lilly | Jul 2009 | 53 |
| NCT00409006Carcinoma, Non-Small-Cell Lung · China, Korea, Republic of, Taiwan | 2 | Completed | Eli Lilly | Aug 2009 | 70 |
| NCT00391274Carcinoma, Non-Small-Cell Lung · China | 3 | Completed | Eli Lilly | Dec 2008 | 211 |
| NCT00386815Mesothelioma, Malignant · Japan | 2 | Completed | Eli Lilly | 20 | |
| NCT00383331Carcinoma, Non-Small-Cell Lung · United States | 2 | Terminated | Eli Lilly | Jan 2008 | 19 |
| NCT00380718Carcinoma, Non-Small-Cell Lung · Taiwan | 4 | Completed | Eli Lilly | Sep 2008 | 33 |
| NCT00377520Neoplasms · United States | 2 | Completed | Eli Lilly | Oct 2007 | 27 |
| NCT00374868Urologic Neoplasms · Spain | 2 | Completed | Eli Lilly | Apr 2008 | 59 |
| NCT00370292Carcinoma, Non-Small-Cell Lung · Italy | 2 | Completed | Eli Lilly | Sep 2008 | 19 |
| NCT00363415Small Cell Lung Carcinoma · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Jun 2008 | 908 |
| NCT00356525Lung Neoplasms · United States, Brazil, India | 2 | Terminated | Eli Lilly | Jun 2008 | 41 |
| NCT00350792Carcinoma, Non-Small-Cell Lung · France | 2 | Completed | Eli Lilly | Nov 2008 | 62 |
| NCT00343720Carcinoma, Non-Small-Cell Lung · Belgium | 2 | Completed | Takeda | Oct 2007 | |
| NCT00330915Rectal Neoplasms · Sweden | 2 | Completed | Eli Lilly | Jun 2008 | 37 |
| NCT00325234Breast Neoplasms · Germany, Italy, South Africa and more | 2 | Completed | Eli Lilly | Apr 2010 | 135 |
How it is read
Names in the registry
- “Pemetrexed”, 74 entries
- “pemetrexed”, 51 entries
- “ALIMTA”, 7 entries
- “Pemetrexed/Cisplatin”, 2 entries
- “Pemetrexed/Carboplatin”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 73 studies
- Breast Neoplasms, 9 studies
- Neoplasms, 5 studies
- Ovarian Neoplasms, 4 studies
- Colorectal Neoplasms, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.